Responses to induction
| . | All (N = 108) . | Myeloablative (n = 54) . | Nonmyeloablative (n = 54) . | P value . |
|---|---|---|---|---|
| Response, n (%) | ||||
| CR | 29 (27) | 12 (22) | 17 (31) | |
| CRu | 25 (23) | 18 (33) | 7 (13) | |
| PR | 24 (22) | 14 (26) | 10 (19) | .047 |
| SD | 8 (7) | 4 (7) | 4 (7) | |
| PD | 18 (17) | 5 (9) | 13 (24) | |
| Not Evaluated | 4 (4) | 1 (2) | 3 (6) | |
| CR [CR/CRu], n (%) | 54 (50) | 30 (56) | 24 (44) | .17 |
| Overall objective response [CR/CRu/PR], n (%) | 78 (72) | 44 (81) | 34 (63) | .026 |
| Clinical benefit rate [CR/CRu/PR/SD], n (%) | 86 (80) | 48 (89) | 38 (70) | .015 |
| . | All (N = 108) . | Myeloablative (n = 54) . | Nonmyeloablative (n = 54) . | P value . |
|---|---|---|---|---|
| Response, n (%) | ||||
| CR | 29 (27) | 12 (22) | 17 (31) | |
| CRu | 25 (23) | 18 (33) | 7 (13) | |
| PR | 24 (22) | 14 (26) | 10 (19) | .047 |
| SD | 8 (7) | 4 (7) | 4 (7) | |
| PD | 18 (17) | 5 (9) | 13 (24) | |
| Not Evaluated | 4 (4) | 1 (2) | 3 (6) | |
| CR [CR/CRu], n (%) | 54 (50) | 30 (56) | 24 (44) | .17 |
| Overall objective response [CR/CRu/PR], n (%) | 78 (72) | 44 (81) | 34 (63) | .026 |
| Clinical benefit rate [CR/CRu/PR/SD], n (%) | 86 (80) | 48 (89) | 38 (70) | .015 |
CRu, unconfirmed CR; PR, partial remission; SD, stable disease.